(BIOG-B) BioGaia (publ) - Ratings and Ratios
Drops, Solutions, Tablets, Lozenges, Cultures
BIOG-B EPS (Earnings per Share)
BIOG-B Revenue
Description: BIOG-B BioGaia (publ)
BioGaia AB is a Swedish healthcare company specializing in probiotic products for gut, oral, and immune health, operating globally across various regions including Europe, the Middle East, Africa, the US, and the Asia-Pacific. The company is structured into three main segments: Pediatrics, Adult Health, and Other, catering to different demographics and product needs.
The Pediatrics segment is a key area, offering products such as drops, oral rehydration solutions, and gut health tablets, as well as cultures used in infant and milk formula. This segment is crucial given the growing demand for infant nutrition and health products. The Adult Health segment also presents significant opportunities, providing products like gut health tablets, bone health tablets, and oral health lozenges, alongside cultures for dairy products.
To further analyze BioGaias performance, we can look at key performance indicators (KPIs) such as revenue growth, gross margin, and operating margin. Given the companys focus on probiotics, a growing market driven by increasing health awareness, we can expect a positive revenue trajectory. The gross margin is likely healthy due to the companys manufacturing capabilities and the premium nature of probiotic products. Operating margin is also a key metric, reflecting the companys efficiency in managing its distribution channels and partnerships.
From a financial standpoint, BioGaias market capitalization stands at approximately 10.3 billion SEK, with a price-to-earnings ratio of 33.99, indicating a relatively high valuation. However, the return on equity (RoE) of 18.50% suggests that the company is generating substantial returns for its shareholders, which is a positive indicator of its financial health and operational efficiency.
Overall, BioGaias diversified product portfolio, global presence, and strong financials position it well in the competitive healthcare and biotechnology sector. Its commitment to probiotic research and development, along with strategic distribution partnerships, are likely to drive future growth.
Additional Sources for BIOG-B Stock
BIOG-B Stock Overview
| Market Cap in USD | 1,100m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception |
BIOG-B Stock Ratings
| Growth Rating | 3.46 |
| Fundamental | 55.5 |
| Dividend Rating | 61.7 |
| Rel. Strength | -9.01 |
| Analysts | - |
| Fair Price Momentum | 87.61 SEK |
| Fair Price DCF | 62.04 SEK |
BIOG-B Dividends
| Dividend Yield 12m | 1.90% |
| Yield on Cost 5y | 1.85% |
| Annual Growth 5y | 20.43% |
| Payout Consistency | 95.9% |
| Payout Ratio | 49.6% |
BIOG-B Growth Ratios
| Growth Correlation 3m | 0.8% |
| Growth Correlation 12m | -47.4% |
| Growth Correlation 5y | 57.3% |
| CAGR 5y | -1.37% |
| CAGR/Max DD 5y | -0.03 |
| Sharpe Ratio 12m | -0.98 |
| Alpha | -28.75 |
| Beta | 0.287 |
| Volatility | 39.89% |
| Current Volume | 220.9k |
| Average Volume 20d | 108.3k |
| Stop Loss | 95.5 (-3%) |
As of August 01, 2025, the stock is trading at SEK 98.50 with a total of 220,930 shares traded.
Over the past week, the price has changed by -1.40%, over one month by -7.25%, over three months by -2.10% and over the past year by -21.30%.
Partly, yes. Based on ValueRay´s Fundamental Analyses, BioGaia (publ) (ST:BIOG-B) is currently (August 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 55.49 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BIOG-B is around 87.61 SEK . This means that BIOG-B is currently overvalued and has a potential downside of -11.06%.
BioGaia (publ) has no consensus analysts rating.
According to our own proprietary Forecast Model, BIOG-B BioGaia (publ) will be worth about 97.3 in August 2026. The stock is currently trading at 98.50. This means that the stock has a potential downside of -1.18%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 150 | 52.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 97.3 | -1.2% |